Previous treatment influences fingolimod efficacy in relapsing–remitting multiple sclerosis: results from an observational study

References

• Kappos L, Radue E-W, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol 2013;260:2023-32
   PubMed Web of Science ®Google Scholar
• EMA approval information about Gilenya. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002202/WC500104530.pdf [Last accessed 19 December 2013]
   Google Scholar
• Determina AIFA (G.U. n. 194 del 21 agosto 2012). Available at: http://www.agenziafarmaco.gov.it/sites/default/files/determina_aifa_g.u._n._194_del_21_agosto_2012.pdf [Last accessed 19 December 2013]
   Google Scholar
• European Medicine Agency (EMA). Available at: www.ema.europa,eu/docs/en_GB/document_library/Press_release/2009/12/WC500017516.pdf [Last accessed 16 April 2014]
   Google Scholar
• StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP, 2009
   Google Scholar
• Rinaldi F, Seppi D, Calabrese M, et al. Switching therapy from natalizumab to fingolimod in relapsing–remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Mult Scler 2012;18:1640-3
   PubMed Web of Science ®Google Scholar
• Schmouder R, Hariry S, David OJ. Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers. Eur J Clin Pharmacol 2012;68:355-62
   PubMed Web of Science ®Google Scholar
• Sempere AP, Martín-Medina P, Berenguer-Ruiz L, et al. Switching from natalizumab to fingolimod: an observational study. Acta Neurol Scand 2013;128:e6-10
   PubMed Web of Science ®Google Scholar
• O’Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011;76:1858-65
   PubMed Web of Science ®Google Scholar
• Fox R, Kappos L, Cree B, et al., eds. Effects of a 24-week natalizumab treatment interruption on clinical and radiologic parameters of multiple sclerosis disease activity: the RESTORE study. 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis, 19–22 October 2011, Amsterdam, The Netherlands
   Google Scholar
• Clerico M, De Mercanti S, Piazza F, et al. Natalizumab discontinuation after the 24th course: which is way? The TY-STOP Study (P01.197). Neurology 2013;80(Meeting Abstracts 1):P01.197
   Google Scholar
• Capobianco M, Di Sapio A, Malentacchi M, et al. Fingolimod is not able to inhibit multiple sclerosis disease reactivation after natalizumab discontinuation. Neurol Sci 2013;34(Suppl):S33
   PubMed Web of Science ®Google Scholar
• Laroni A, Brogi D, Milesi V, et al. Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption. Mult Scler 2013;19:1236-7
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, Comi G, et al. Disease control and safety in relapsing–remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: a 32-week, rater- and patient-blind, randomized, parallel-group study (TOFINGO). Mult Scler 2013;19(S1):50
   Google Scholar
• Roedegher M, Messina M, Rocca M, et al. Previous treatments influence disease activity during fingolimod therapy in multiple sclerosis patients. Neurol Sci 2013;34(Suppl):S33
   PubMed Web of Science ®Google Scholar
• Evangelopulos ME, Andreadou E, Panagiotou M, et al. Follow up of multiple sclerosis patients receiving fingolimod treatment: switching from natalizumab to treatment with fingolimod, clinical and MRI findings. Mult Scler 2013;19(S1):243
   Google Scholar
• Totaro R, Costantino G, Fantozzi R, et al. Efficacy of fingolimod treatment in multiple sclerosis patients: a multicentre experience in clinical practice in Italy. Mult Scler 2013;19(S1):479
   Google Scholar
• Jokubaitis VG, Li V, Kalincik T, et al. Does switching to fingolimod from natalizumab result in a short-term relapse exacerbation? Mult Scler 2013;19(S1):55
   Google Scholar
• Cohen M, Maillart E, Papeix S, et al. Switching from natalizumab to fingolimod: risk of disease reactivation during the washout period is due to the previous activity of disease. Follow-up of the ENIGM survey. Mult Scler 2013;19(S1):269
   Google Scholar
• Messina MJ, Rodegher M, Baroncini D, et al. Can fingolimod treatment influence disease progression after natalizumab discontinuation? Mult Scler 2013;19(S1):26
   PubMed Web of Science ®Google Scholar
• Baroncini D, Ghezzi A, Annovazzi P, et al. Fingolimod in real clinical practice – a second line treatment? Neurol Sci 2013;34(Suppl):S161
   PubMed Web of Science ®Google Scholar
• Romera M, Fernandez-Bolanos R, Rus M, et al. An observational study of switching from natalizumab to fingolimod. Mult Scler 2013;19(S1):463
   Google Scholar
• Rinaldi F, Miante S, Perini P, et al. Clinical and MRI outcomes in fingolimod-treated relapsing remitting multiple sclerosis (RRMS) patients previously exposed to natalizumab: an 18-month follow-up. Mult Scler 2013;19(S1):249
   PubMed Web of Science ®Google Scholar
• Centonze D, Rossi S, Rinaldi F, et al. Severe relapses under fingolimod treatment prescribed after natalizumab. Neurology 2012;79:2004-5
   PubMed Web of Science ®Google Scholar
• Jander S, Turowski B, Kieseier BC, et al. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler 2012;18:1650-2
   PubMed Web of Science ®Google Scholar
• Castrop F, Kowarik MC, ALbrecht H, et al. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence? Neurology 2012;78:928-30
   PubMed Web of Science ®Google Scholar
• Wolf AM, Eller K, Zeiser R, et al. The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. J Immunol 2009;183:3751-60
   PubMed Web of Science ®Google Scholar